BioTeZ Berlin-Buch GmbH aus Berlin auf der MEDICA 2019 in Düsseldorf -- COMPAMED Messe
Standverwaltung
Option auswählen
Hersteller

BioTeZ Berlin-Buch GmbH

Robert-Rössle-Str. 10, 13125 Berlin
Deutschland
Telefon +49 30 94892130
Fax +49 30 9494509
info@biotez.de

Dieser Aussteller ist Mitaussteller von
DiagnostikNet-BB Netzwerk Diagnostik Berlin-Brandenburg e.V.

Hallenplan

MEDICA 2019 Hallenplan (Halle 3): Stand G54

Geländeplan

MEDICA 2019 Geländeplan: Halle 3

Ansprechpartner

Dr. Janko Brand

Senior Scientist

Berlin

Telefon
03094893318

E-Mail
J.brand@biotez.de

Uwe Ahnert

CEO

Berlin

Telefon
03094893318

E-Mail
info@biotez.de

Besuchen Sie uns!

Halle 3 / G54

18.11.2019

Thema

ganztägig

Presentation on Therapeutic Drug/Antigen Monitoring- Adalimumab, Evolocumab, Infliximab and Omalizumab

BioTeZ established a novel therapeutic drug monitoring assay for Evolocumab and PCSK9

The first PCSK9 Inhibitors reach the market and BioTeZ just completed the development project for the therapeutic drug and antigen monitoring assay. The recoveryELISA® (RPE) allows the simultaneous quantification of the free PCSK9 and the free Evolocumab in one ELISA assay.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has medical importance since it directly interferes with the lipoprotein particles (LDL) homeostasis. PCSK9 binds to the lipoprotein particles receptor (LDLR) which transports fat molecules within the extracellular fluid. Agents which block PCSK9 can decrease the LDL particle concentrations in the blood and thereby prevent cardiovascular disease.

The first therapeutic monoclonal antibodies against PCSK9 Evolocumab and Alirocumab were approved by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.

For Evolocumab two different dosing regimes are suggested 140 mg every two weeks or 420 mg once per month. By definition Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drugs to maintain a constant concentration in a patient's bloodstream, thereby optimizing individual dosage regimes (1).

“The recoveryELISA® RPE is the only method that simultaneously quantifies the free PCSK9, the PCSK9 neutralization rate and the free available therapeutic antibody Evolocumab in human serum samples during Evolocumab therapy. With our new recoveryELISA® RPE we support TDM studies and can contribute for a truly personalized dose finding strategy” explains Uwe Ahnert (CEO of BioTeZ).

A pilot study enrolled Evolocumab naïve patients suffering from residual cardiovascular disease, treated for the first time with evolocumab and followed for the next two injections. Serum samples were tested with the recoveryELISA© RPE to quantify free PCSK9 and free evolocumab simultaneously and compared these results with the lipid profile.

“We are glad to demonstrate the ability of the recoveryELISA© PCSK9 & Evolocumab for this important application in a clinical setting. Currently, we evaluate the data and we will start soon with writing up a publication on our findings” says Dr. Janko Brand (senior Scientist at BioTeZ).

About BioTeZ: BioTeZ is a 1992 founded Biotech Company, developing and producing ELISA kits, protease activity kits, antibodies, diagnostics and oligonucleotides. BioTeZ has longstanding experience in the development of biochemical test procedures for research institutes, hospitals and laboratories worldwide. BioTeZ hold all relevant patents on the recoveryELISA© and the technology was previously established for Omalizumab/IgE (2), Infliximab/TNFa (3), Adalimumab/TNFa (4) and customized for clients  involved in early biological development projects from the pharmaceutical industry.

References:

1.         Kang J-S, Lee M-H. Overview of Therapeutic Drug Monitoring. Korean J Intern Med [Internet] 2009 [cited 2018 Sep 21];24:1-10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687654/

2.         Gericke J, Metz M, Ohanyan T, Weller K, Altrichter S, Skov PS, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol 2017;139:1059-1061.e1.

3.         Strohner P, Staatz A, Sarrach D, Steiss J-O, Becher G. The recoveryELISA--a newly developed immunoassay for measurement of therapeutic antibodies and the target antigen during antibody therapy. Clin Chem Lab Med 2012;50:1263-9.

4.         Zänker M, Becher G, Arbach O, Maurer M, Stuhlmüller B, Schäfer A, et al. Improved adalimumab dose decision with comprehensive diagnostics data. Clin Exp Rheumatol 2018;36:136-9.

Mehr Weniger

ganztägig

Tour de BioTeZ

We are happy to give you "Tour De BoTeZ" and walk you through the product & services we offer!

We provide You with the best biotechnology products and services that ensure high quality and innovation.
Founded in 1992 and ISO 9001:2015 certified, BioTeZ supports the research in many areas, both on the Biotechnology Campus Berlin-Buch, Germany, as well as in facilities around the world. For 25 years, we are continuously motivated for new challenges to meet Your needs. Since 2019 Steffens-Biotec, Ebringen, ISO 13485 certified is a sister company of BioTeZ specialized in manufacturing CE in-vitro diagnostics.  We are specialized in immunochemistry and the development and production of high-quality components for ELISA, Immuno Assays & Protease Activity Kits, Immuno Affinity Chromatography and Lateral Flow Tests.

Mehr Weniger

19.11.2019

Thema

ganztägig

Presentation on Therapeutic Drug/Antigen Monitoring- Adalimumab, Evolocumab, Infliximab and Omalizumab

BioTeZ established a novel therapeutic drug monitoring assay for Evolocumab and PCSK9

The first PCSK9 Inhibitors reach the market and BioTeZ just completed the development project for the therapeutic drug and antigen monitoring assay. The recoveryELISA® (RPE) allows the simultaneous quantification of the free PCSK9 and the free Evolocumab in one ELISA assay.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has medical importance since it directly interferes with the lipoprotein particles (LDL) homeostasis. PCSK9 binds to the lipoprotein particles receptor (LDLR) which transports fat molecules within the extracellular fluid. Agents which block PCSK9 can decrease the LDL particle concentrations in the blood and thereby prevent cardiovascular disease.

The first therapeutic monoclonal antibodies against PCSK9 Evolocumab and Alirocumab were approved by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.

For Evolocumab two different dosing regimes are suggested 140 mg every two weeks or 420 mg once per month. By definition Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drugs to maintain a constant concentration in a patient's bloodstream, thereby optimizing individual dosage regimes (1).

“The recoveryELISA® RPE is the only method that simultaneously quantifies the free PCSK9, the PCSK9 neutralization rate and the free available therapeutic antibody Evolocumab in human serum samples during Evolocumab therapy. With our new recoveryELISA® RPE we support TDM studies and can contribute for a truly personalized dose finding strategy” explains Uwe Ahnert (CEO of BioTeZ).

A pilot study enrolled Evolocumab naïve patients suffering from residual cardiovascular disease, treated for the first time with evolocumab and followed for the next two injections. Serum samples were tested with the recoveryELISA© RPE to quantify free PCSK9 and free evolocumab simultaneously and compared these results with the lipid profile.

“We are glad to demonstrate the ability of the recoveryELISA© PCSK9 & Evolocumab for this important application in a clinical setting. Currently, we evaluate the data and we will start soon with writing up a publication on our findings” says Dr. Janko Brand (senior Scientist at BioTeZ).

About BioTeZ: BioTeZ is a 1992 founded Biotech Company, developing and producing ELISA kits, protease activity kits, antibodies, diagnostics and oligonucleotides. BioTeZ has longstanding experience in the development of biochemical test procedures for research institutes, hospitals and laboratories worldwide. BioTeZ hold all relevant patents on the recoveryELISA© and the technology was previously established for Omalizumab/IgE (2), Infliximab/TNFa (3), Adalimumab/TNFa (4) and customized for clients  involved in early biological development projects from the pharmaceutical industry.

References:

1.         Kang J-S, Lee M-H. Overview of Therapeutic Drug Monitoring. Korean J Intern Med [Internet] 2009 [cited 2018 Sep 21];24:1-10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687654/

2.         Gericke J, Metz M, Ohanyan T, Weller K, Altrichter S, Skov PS, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol 2017;139:1059-1061.e1.

3.         Strohner P, Staatz A, Sarrach D, Steiss J-O, Becher G. The recoveryELISA--a newly developed immunoassay for measurement of therapeutic antibodies and the target antigen during antibody therapy. Clin Chem Lab Med 2012;50:1263-9.

4.         Zänker M, Becher G, Arbach O, Maurer M, Stuhlmüller B, Schäfer A, et al. Improved adalimumab dose decision with comprehensive diagnostics data. Clin Exp Rheumatol 2018;36:136-9.

Mehr Weniger

ganztägig

Tour de BioTeZ

We are happy to give you "Tour De BoTeZ" and walk you through the product & services we offer!

We provide You with the best biotechnology products and services that ensure high quality and innovation.
Founded in 1992 and ISO 9001:2015 certified, BioTeZ supports the research in many areas, both on the Biotechnology Campus Berlin-Buch, Germany, as well as in facilities around the world. For 25 years, we are continuously motivated for new challenges to meet Your needs. Since 2019 Steffens-Biotec, Ebringen, ISO 13485 certified is a sister company of BioTeZ specialized in manufacturing CE in-vitro diagnostics.  We are specialized in immunochemistry and the development and production of high-quality components for ELISA, Immuno Assays & Protease Activity Kits, Immuno Affinity Chromatography and Lateral Flow Tests.

Mehr Weniger

20.11.2019

Thema

ganztägig

Presentation on Therapeutic Drug/Antigen Monitoring- Adalimumab, Evolocumab, Infliximab and Omalizumab

BioTeZ established a novel therapeutic drug monitoring assay for Evolocumab and PCSK9

The first PCSK9 Inhibitors reach the market and BioTeZ just completed the development project for the therapeutic drug and antigen monitoring assay. The recoveryELISA® (RPE) allows the simultaneous quantification of the free PCSK9 and the free Evolocumab in one ELISA assay.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has medical importance since it directly interferes with the lipoprotein particles (LDL) homeostasis. PCSK9 binds to the lipoprotein particles receptor (LDLR) which transports fat molecules within the extracellular fluid. Agents which block PCSK9 can decrease the LDL particle concentrations in the blood and thereby prevent cardiovascular disease.

The first therapeutic monoclonal antibodies against PCSK9 Evolocumab and Alirocumab were approved by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.

For Evolocumab two different dosing regimes are suggested 140 mg every two weeks or 420 mg once per month. By definition Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drugs to maintain a constant concentration in a patient's bloodstream, thereby optimizing individual dosage regimes (1).

“The recoveryELISA® RPE is the only method that simultaneously quantifies the free PCSK9, the PCSK9 neutralization rate and the free available therapeutic antibody Evolocumab in human serum samples during Evolocumab therapy. With our new recoveryELISA® RPE we support TDM studies and can contribute for a truly personalized dose finding strategy” explains Uwe Ahnert (CEO of BioTeZ).

A pilot study enrolled Evolocumab naïve patients suffering from residual cardiovascular disease, treated for the first time with evolocumab and followed for the next two injections. Serum samples were tested with the recoveryELISA© RPE to quantify free PCSK9 and free evolocumab simultaneously and compared these results with the lipid profile.

“We are glad to demonstrate the ability of the recoveryELISA© PCSK9 & Evolocumab for this important application in a clinical setting. Currently, we evaluate the data and we will start soon with writing up a publication on our findings” says Dr. Janko Brand (senior Scientist at BioTeZ).

About BioTeZ: BioTeZ is a 1992 founded Biotech Company, developing and producing ELISA kits, protease activity kits, antibodies, diagnostics and oligonucleotides. BioTeZ has longstanding experience in the development of biochemical test procedures for research institutes, hospitals and laboratories worldwide. BioTeZ hold all relevant patents on the recoveryELISA© and the technology was previously established for Omalizumab/IgE (2), Infliximab/TNFa (3), Adalimumab/TNFa (4) and customized for clients  involved in early biological development projects from the pharmaceutical industry.

References:

1.         Kang J-S, Lee M-H. Overview of Therapeutic Drug Monitoring. Korean J Intern Med [Internet] 2009 [cited 2018 Sep 21];24:1-10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687654/

2.         Gericke J, Metz M, Ohanyan T, Weller K, Altrichter S, Skov PS, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol 2017;139:1059-1061.e1.

3.         Strohner P, Staatz A, Sarrach D, Steiss J-O, Becher G. The recoveryELISA--a newly developed immunoassay for measurement of therapeutic antibodies and the target antigen during antibody therapy. Clin Chem Lab Med 2012;50:1263-9.

4.         Zänker M, Becher G, Arbach O, Maurer M, Stuhlmüller B, Schäfer A, et al. Improved adalimumab dose decision with comprehensive diagnostics data. Clin Exp Rheumatol 2018;36:136-9.

Mehr Weniger

ganztägig

Tour de BioTeZ

We are happy to give you "Tour De BoTeZ" and walk you through the product & services we offer!

We provide You with the best biotechnology products and services that ensure high quality and innovation.
Founded in 1992 and ISO 9001:2015 certified, BioTeZ supports the research in many areas, both on the Biotechnology Campus Berlin-Buch, Germany, as well as in facilities around the world. For 25 years, we are continuously motivated for new challenges to meet Your needs. Since 2019 Steffens-Biotec, Ebringen, ISO 13485 certified is a sister company of BioTeZ specialized in manufacturing CE in-vitro diagnostics.  We are specialized in immunochemistry and the development and production of high-quality components for ELISA, Immuno Assays & Protease Activity Kits, Immuno Affinity Chromatography and Lateral Flow Tests.

Mehr Weniger

21.11.2019

Thema

ganztägig

Presentation on Therapeutic Drug/Antigen Monitoring- Adalimumab, Evolocumab, Infliximab and Omalizumab

BioTeZ established a novel therapeutic drug monitoring assay for Evolocumab and PCSK9

The first PCSK9 Inhibitors reach the market and BioTeZ just completed the development project for the therapeutic drug and antigen monitoring assay. The recoveryELISA® (RPE) allows the simultaneous quantification of the free PCSK9 and the free Evolocumab in one ELISA assay.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has medical importance since it directly interferes with the lipoprotein particles (LDL) homeostasis. PCSK9 binds to the lipoprotein particles receptor (LDLR) which transports fat molecules within the extracellular fluid. Agents which block PCSK9 can decrease the LDL particle concentrations in the blood and thereby prevent cardiovascular disease.

The first therapeutic monoclonal antibodies against PCSK9 Evolocumab and Alirocumab were approved by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.

For Evolocumab two different dosing regimes are suggested 140 mg every two weeks or 420 mg once per month. By definition Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drugs to maintain a constant concentration in a patient's bloodstream, thereby optimizing individual dosage regimes (1).

“The recoveryELISA® RPE is the only method that simultaneously quantifies the free PCSK9, the PCSK9 neutralization rate and the free available therapeutic antibody Evolocumab in human serum samples during Evolocumab therapy. With our new recoveryELISA® RPE we support TDM studies and can contribute for a truly personalized dose finding strategy” explains Uwe Ahnert (CEO of BioTeZ).

A pilot study enrolled Evolocumab naïve patients suffering from residual cardiovascular disease, treated for the first time with evolocumab and followed for the next two injections. Serum samples were tested with the recoveryELISA© RPE to quantify free PCSK9 and free evolocumab simultaneously and compared these results with the lipid profile.

“We are glad to demonstrate the ability of the recoveryELISA© PCSK9 & Evolocumab for this important application in a clinical setting. Currently, we evaluate the data and we will start soon with writing up a publication on our findings” says Dr. Janko Brand (senior Scientist at BioTeZ).

About BioTeZ: BioTeZ is a 1992 founded Biotech Company, developing and producing ELISA kits, protease activity kits, antibodies, diagnostics and oligonucleotides. BioTeZ has longstanding experience in the development of biochemical test procedures for research institutes, hospitals and laboratories worldwide. BioTeZ hold all relevant patents on the recoveryELISA© and the technology was previously established for Omalizumab/IgE (2), Infliximab/TNFa (3), Adalimumab/TNFa (4) and customized for clients  involved in early biological development projects from the pharmaceutical industry.

References:

1.         Kang J-S, Lee M-H. Overview of Therapeutic Drug Monitoring. Korean J Intern Med [Internet] 2009 [cited 2018 Sep 21];24:1-10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687654/

2.         Gericke J, Metz M, Ohanyan T, Weller K, Altrichter S, Skov PS, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol 2017;139:1059-1061.e1.

3.         Strohner P, Staatz A, Sarrach D, Steiss J-O, Becher G. The recoveryELISA--a newly developed immunoassay for measurement of therapeutic antibodies and the target antigen during antibody therapy. Clin Chem Lab Med 2012;50:1263-9.

4.         Zänker M, Becher G, Arbach O, Maurer M, Stuhlmüller B, Schäfer A, et al. Improved adalimumab dose decision with comprehensive diagnostics data. Clin Exp Rheumatol 2018;36:136-9.

Mehr Weniger

ganztägig

Tour de BioTeZ

We are happy to give you "Tour De BoTeZ" and walk you through the product & services we offer!

We provide You with the best biotechnology products and services that ensure high quality and innovation.
Founded in 1992 and ISO 9001:2015 certified, BioTeZ supports the research in many areas, both on the Biotechnology Campus Berlin-Buch, Germany, as well as in facilities around the world. For 25 years, we are continuously motivated for new challenges to meet Your needs. Since 2019 Steffens-Biotec, Ebringen, ISO 13485 certified is a sister company of BioTeZ specialized in manufacturing CE in-vitro diagnostics.  We are specialized in immunochemistry and the development and production of high-quality components for ELISA, Immuno Assays & Protease Activity Kits, Immuno Affinity Chromatography and Lateral Flow Tests.

Mehr Weniger

Unser Angebot

Produktkategorien

  • 03  Diagnostika
  • 03.02  Immunochemie / Immunologie
  • 03.02.02  Diagnose-Schnelltests
  • 03  Diagnostika
  • 03.05  Infektionsimmunologie
  • 03.05.01  Bakteriologie-Tests in der Infektionsimmunologie

Bakteriologie-Tests in der Infektionsimmunologie

Unsere Produkte

Produktkategorie: Immun-Assay-Systeme, Sonstige Diagnostika

Rheumatoide Arthritis in Zeiten der Therapieoptimierung

Anti-TNF-alpha-Antikörper wie Adalimumab verbessern die Therapie der rheumatoiden Arthritis erheblich. Dennoch gibt es Fälle, bei denen der Antikörper unzureichend wirkt oder Nebenwirkungen auftreten. Um die Therapie zu optimieren, bedarf es einer gezielten Dosisanpassung der Wirkstoffe für jeden Patienten. Die BioTeZ Berlin-Buch GmbH hat ein Immunoassay-Verfahren entwickelt, welches den Medikamentenspiegel bestimmt und es erlaubt, die Wirkstoffdosis bestmöglich anzupassen.

Mehr Weniger

Produktkategorie: Immun-Assay-Systeme, Bakteriologie-Tests in der Infektionsimmunologie, Sonstige Diagnostika

Humandiagnostische ELISA (IVD) nach ISO 13485:2016 produziert

Diese ELISAs tragen das CE-Zeichen und entsprechen dem üblichen Format mit 96 Analysen. Sie alle verwenden identische allgemeine Reagenzien, nämlich Probenpuffer, Waschpuffer, Substrat und Stoplösung. Daher kann ein und dieselbe Probenverdünnung für mehrere Tests verwendet werden, bspw. zur gleichzeitigen Bestimmung von Cardiolipin-IgG und -IgM.

Alle Lösungen sind gebrauchsfertig (Ausnahme: Waschpuffer 10x-Konzentrat) und farbcodiert. Die Konjugatfarbe (rot, gelb oder grün) zeigt an, welche Ig-Klasse detektiert wird, IgG, IgA bzw. IgM. Die Farbintensität der blauen Kalibratoren spiegelt ihre jeweilige Konzentration wider. Die negative Kontrolle ist grün, die positive rot.

Die Festphase besteht aus abbrechbaren Einzel-Kavitäten und erlaubt so einen ökonomischen Einsatz der Kits. Sie ist hermetisch verpackt in einem wieder-verschließbaren Folienbeutel; nützlich bei nur teilweisem Festphasen-Verbrauch. Auf dem Rahmen der Festphase ist der Messparameter-Name angegeben.

Die Probe ist Serum oder Plasma, durchgängig werden 10 µL benötigt. Sie wird 1:100 im orange-farbenen Probenpuffer verdünnt. 100 µL pro Kavität ist das einheitliche Volumen von Probe, Konjugat, Substrat und Stoplösung.

Die Tests haben ein einheitliches Protokoll: 3 x 30 Minuten Inkubation bei Raumtemperatur, ohne Schütteln. Gewaschen wird immer mit 4 x 350 µL pro Kavität.

Sie wurden auf dem Dynex DS2-System validiert und sind auch für andere Automaten geeignet. Die Lösungen kommen in PE-Fläschchen mit ausreichend Volumen für die Automatisierung des Tests. Das Detektionssystem ist HRP/TMB; gemessen wird bei 450 nm.

Die kompakte Box der Kits ist auf zwei Seiten beschriftet, damit man sie in Kühlschrank-Stapeln leicht erkennen kann. Jedes Produkt enthält die Gebrauchsinformation in gedruckter Form (auch herunterladbar) mit einer Kurzanleitung auf der Rückseite. Außerdem wird ein Chargen-spezifisches Analysen-Zertifikat mitgeliefert. Die meisten Tests bieten die Wahl zwischen qualitativer und quantitativer Auswertung.

Die exzellente Qualität dieses Tests schlägt sich in einer jahrelang sehr geringen Zahl an Reklamationen nieder. Seit über einem Jahrzehnt nehmen wir regelmäßig an mehreren internationalen Ringversuchen teil (UK: Neqas, US: CAP, Deutschland: Instand sowie Referenzinstitut für Bioanalytik) mit praktisch keinerlei Abweichungen unserer Messungen vom jeweils erwarteten Resultat.Steffens Biotechnische Analysen GmbH unterhält ein Qualitätsmanagement-System, das die Anforderungen des Regelwerks ISO 13485:2016 erfüllt.

Mehr Weniger

Produktkategorie: Diagnose-Schnelltests

The TA-PAS labelling Kit as alternative to the classical Biotin-Streptavidin system

The TA-PAS System is a fast two component protein-ligand interaction system. One component is the small synthetic label called “TA-Label” (<1000 Da). The second component is the “PAS-Antibody” which binds the “TA-Label” with high specificity and efficiency.

The TA-PAS System supports a large number of applications including immobilization, enrichment or detection of antibodies, other proteins, primers and other nucleic acids. The TA-PAS System is a simple yet elegant system to link TA labelled molecules in assays by exploiting the high affinity to PAS capture antibody.

  • Fast binding universal detection system, e.g. lateral flow assay
  • ELISA, it can be used as detection or coating component
  • Immunohistochemistry (IHC)
  • Western-, Southern- und Northern Blot
  • Immunoaffinity chromatography
  • Cell surface labelling etc.
  • Alternative to Biotin-Streptavidin or in combination with Biotin-Streptavidin
  • TA-PAS with double labelled molecules like primers, antibodies, Proteins
  • Immunoprecipitation: Immobilization of target molecules from cell culture or other biological samples
  • Target molecule enrichment
  •  Application Example: Lateral Flow Test 
Application of TA-PAS system in lateral flow in combination with a double labelling strategy (antibody conjugated with Gold nanoparticles and TA-Label) for immobilization at control line and streptavidin/biotin system for test line.

Advantages of the TA-PAS System compared with a clasical Biotin-Streptavidin System

  • The TA-PAS system allows a flexible, simple use in many applications
  • Improvement of signal-noise ratio
  • High affinity binding between TA-Label and PAS-Antibody (capture antibody)
  • Fast Binding
  • Low cross-reactivity
  • Low non-specific binding
  • TA-PAS interaction is artificial and not present in nature
  • No problems with samples or proteins with biotin (e.g. Carboxylases, Histones)
  • pH-stable
  • Long shelf life time
  • Reproducible results
  • No problems with PAS coating followed by blocking with serum
  • No problems with double labelling strategies for lateral flow test
  • Application Example: Immobilisation of TA-labelled Molecules for Target molecule enrichment
The TA-PAS labelling kit allows antibodies, proteins, primer etc. to be covalently labelled with the TA-Label quickly and easily. The pre-activated TA-Label is designated for the coupling reaction with target molecules through the reaction with primary amino groups. BioTeZ TA-PAS labelling kit includes the PAS-Antibody (capture antibody), all necessary reagents to label the target molecule with the TA-Labels and a clean-up column for purifying the coupling product (separation of unbound labels). Generally the TA-Label is fully compatible with other labels and should work well.  

For more details please read the product data sheet.

Mehr Weniger

Produktkategorie: Immun-Assay-Systeme

Mykotoxinanalytik & Vitaminanalytik mit Immunoaffinitätssäulen & ELISA

Separation - Purification – Clean up - Enrichment of analytes
Capabilities: million times proofed quality, excellent flow behavior, robustness, high permeability, working without extra pressure.

Mycotoxins
B-TeZ Combi AOZDFT for LC-MS/MS: Multi IAC for 11 regulated Mycotoxins Aflatoxin; Ochratoxin; Zearalenon; DON; Fumonisin; T2HT2 Size 3ml; BTCM326005
B-TeZ IAC Aflatoxin; Size 3ml; BTAF310005
B-TeZ IAC Aflatoxin M1; Size 3ml; BTAFM311005
B-TeZ IAC Aflatoxin M1; Size 1ml; BTAFM111005
B-TeZ IAC Ochratoxin; Size 3ml; BTOT312005
B-TeZ IAC Ochratoxin; Size 1ml; BTOT112005
B-TeZ IAC Combi Aflatoxin + Ochratoxin; Size 3ml; BTCA321005
B-TeZ IAC Combi Aflatoxin + Ochratoxin; Size 1ml; BTCA121005
B-TeZ IAC Combi Aflatoxin + Ochratoxin; Size 1ml; BTCA121005
B-TeZ IAC Combi Aflatoxin + Ochratoxin + Zearalenon; Size 3ml; BTCZ322005
any many more, please contact us if you like to order or develop IAC.
info@biotez.de

Mehr Weniger

Firmennews

Datum

Thema

Download

31.10.2019

HUDSON Institute established assay for early detection of preeclampsia

Preeclampsia is a serious disorder of human pregnancy with the risk of a premature birth and life-threatening blood pressure of the mother. The adjustment of the blood pressure as well as the measurement of the excreted protein in urine is of great importance and the early detection of preeclampsia is still a field of extensive research.

“Our major goals are to develop strategies for early detection and treatment of pre-eclampsia, a life-threatening disorder of human pregnancy. In addition, we are interested in the long-term health consequences of placental insufficiency and pregnancy diseases,” says Prof. Guiying Nie from Hudson institute of Medical Research’s Implantation and Placental Development research group. She and her team developed a HtrA3 isoform specific ELISA for the early detection of preeclampsia (1) and a test system for HtrA4 (2).

The ELISAs were validated using the difficult to express HtrA family proteins (high temperature required factor A) HtrA1, HtrA3 and HtrA4 that were purchased from the BioTeZ GmbH. “We are glad to be able to provide valuable reagents for basic research. This helps us to develop new products which can be translated into real innovations for the health sector” says Dr. Anca Marksteder scientist, working for the protein expression facility at BioTeZ.

Preeclampsia can be divided into subtypes of early onset (<34 weeks of gestation) and late onset (>34 weeks). The recently published study examined serum levels of HtrA3 isoforms (Long form, L; total form, T) at 11-13 weeks of gestation in patients who subsequently developed preeclampsia in the 3rd trimester. The results show that compared with controls, the patient’s developed late-onset preeclampsia and had significantly higher levels of HtrA3-L, whereas those who developed early-onset preeclampsia had significantly lower ratios of HtrA3-L/HtrA3-T. This data supports the utility of the HtrA3 ELISAs for early detection of preeclampsia.

Prof. Guiying Nie’s research group is interested in uterine infertility and receptivity for embryo implantation, non-hormonal contraception, endometrial cancer, placental development and diseases of pregnancy in particularly preeclampsia.

Hudson Institute of Medical Research is globally renowned for its ground-breaking research into reproductive and baby health and is a leading center for research into infection and innate immunity. It is one of the largest and most respected medical research institutes in Australia. It has 75 years of research excellence in discoveries included the development of IVF technology, discovery of the hormone Inhibin, which enabled diagnostic tests for Downs Syndrome and ovarian cancers.

BioTeZ is a 1992 founded Biotech Company, developing and producing ELISA kits, protease activity kits, antibodies, diagnostics and oligonucleotides. BioTeZ has longstanding experience in the development of biochemical test procedures for research institutes, hospitals and laboratories worldwide.

1.         Wang Y, Li Y, Hyett J, da Silva Costa F, Nie G. HtrA3 Isoform-Specific ELISAs for Early Detection of Preeclampsia. J Biomol Screen 2016;

2.         Wang Y, Nie G. High levels of HtrA4 observed in preeclamptic circulation drastically alter endothelial gene expression and induce inflammation in human umbilical vein endothelial cells. Placenta 2016;47:46-55.

Mehr Weniger

Über uns

Firmenporträt

Die BioTeZ Berlin-Buch GmbH ist ein 1992 gegründetes Biotechnologieunternehmen. BioTeZ ist Partner von Forschungsinstitutionen, der pharmazeutischen Industrie und Labordiagnostik.

Das Schwesterunternehmen Steffens Biotechnische Analysen GmbH, Ebringen ist auf die Produktion von CE - IVD's spezialisiert und ISO 13485 zertifiziert.

Wir würden uns freuen über Ihre Ideen und Bedürfnisse zu sprechen in den Bereichen:
  • Anreicherung des Zielmolekül mit Immunaffinitätschromatographie
  • Überwachung der Arzneimitteleffizienz mit Antikörpern als Wirkstoffen (TDM)
  • Autoimmun- und diagnostischer ELISA (CE / IVD)
  • ELISA & Schnelltest-Entwicklung
  • Oberflächenfunktionalisierung mit Poly-Streptavidin und TAPAS-Systemen (Biotin-frei)
  • Messung der Proteaseaktivität
  • Oligonukleotide und Aptamere

Mehr Weniger

Unternehmensdaten

Umsatz

1-9 Mio US $

Exportanteil

> 75%

Anzahl der Beschäftigten

20-49

Gründungsjahr

1992

Geschäftsfelder

Diagnostika